Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Sarcoma 1Breast 1

Conditions

Gliosarcoma 4Glioblastoma 4Central Nervous System Neoplasms 2Astrocytoma 2Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Oligodendroglioma 1Neoplasms 1Hemangiosarcoma 1Glioma 1Ependymoma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 48Bevacizumab 29Carmustine 17Erlotinib Hydrochloride 16Radiotherapy 14Irinotecan 14Surgical Procedures, Operative 10Sirolimus 10Imatinib Mesylate 10Carboplatin 10Sorafenib 9O(6)-benzylguanine 9Filgrastim 9Etoposide 8temsirolimus 7sargramostim 7Radiosurgery 7Radiation 7Procarbazine 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7aldesleukin 6Topotecan 6Thalidomide 6Vorinostat 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Hydroxyurea 5Gefitinib 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × veliparib × Sarcoma × Clear all
NCT01026493 2017-07-02

Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Radiation Therapy Oncology Group

Phase 1/2 Completed
257 enrolled 16 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡